IDEXX Laboratories, Inc. (NASDAQ:IDXX) reported $0.89 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.87 by $0.02. The company had revenue of $360.20 million for the quarter, compared to the consensus estimate of $361.58 million. During the same quarter last year, the company posted $0.81 earnings per share. IDEXX Laboratories’s revenue was up 8.5% compared to the same quarter last year. Analysts expect that IDEXX Laboratories will post $3.84 EPS for the current fiscal year. IDEXX Laboratories, Inc. (NASDAQ:IDXX) net profit margin is 16.70% and weekly performance is 2.80%. On last trading day company shares ended up $134.38. Analysts mean target price for the company is $129.14. IDEXX Laboratories, Inc. (NASDAQ:IDXX) distance from 50-day simple moving average (SMA50) is 5.52%.
On 2 JUNE Atossa Genetics Inc (NASDAQ:ATOS) announced that a presentation will be made at the 2014 American Society of Clinical Oncology (ASCO) Conference at McCormick Place, Chicago, Illinois, involving technology that has been licensed to Atossa by A5 Genetics KFT, Corporation. Atossa Genetics Inc (NASDAQ:ATOS) shares fell -7.83% in last trading session and ended the day on $1.53. ATOS Gross Margin is 40.00% and its return on assets is -77.90%. Atossa Genetics Inc (NASDAQ:ATOS) quarterly performance is -15.47%.
On 11 JUNE AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) announced the appointment of Melissa Bradford Klug as senior vice president of business development and strategy. Ms. Klug brings a wealth of hands-on business development, licensing and strategic partnering experience, as well as extensive leadership skills to AMAG’s executive team. AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) shares moved down -0.86% in last trading session and was closed at $20.24, while trading in range of $20.02 – $20.64. AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) year to date (YTD) performance is -16.64%.
On 2 JUNE Quidel Corporation (NASDAQ:QDEL) announced that Quidel has received Clinical Laboratory Improvement Amendments (CLIA) waiver from the U.S. Food and Drug Administration (FDA) for its Sofia RSV Fluorescent Immunoassay (FIA) for the rapid detection of respiratory syncytial virus (RSV). Quidel Corporation (NASDAQ:QDEL) ended the last trading day at $22.13. Company weekly volatility is calculated as 2.91% and price to cash ratio as 30.05. Quidel Corporation (NASDAQ:QDEL) showed a negative weekly performance of -8.33%.
On 21 MAY Venaxis Inc (NASDAQ:APPY) said it focused on obtaining FDA clearance and commercializing its CE Marked APPY1™ Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, announced it will participate in the 11th Annual Craig-Hallum Institutional Investor Conference, to be held, at the Minneapolis Marriott City Center. Venaxis Inc (NASDAQ:APPY) net weekly performance is -1.30%. On last trading day company shares ended up $2.27. Analysts mean target price for the company is $5.67. Venaxis Inc (NASDAQ:APPY) distance from 50-day simple moving average (SMA50) is 7.76%.